Lenacapavir Suppliers & Bulk Manufacturers
Available Forms: Tablet / Injection
Available Strengths: 300 mg, 463.5 mg/1.5 mL
Reference Brands: Yeztugo (USA), Sunlenca (USA)
Category:
Anti Viral
Lenacapavir is available in Tablet / Injection
and strengths such as 300 mg, 463.5 mg/1.5 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Lenacapavir is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Lenacapavir can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Lenacapavir is a long-acting antiretroviral medication used in the treatment of human immunodeficiency virus type 1 (HIV-1) infection, particularly in heavily treatment-experienced patients with multidrug-resistant virus where existing therapies are no longer effective or tolerated. It belongs to a novel class of medicines known as HIV-1 capsid inhibitors and works by targeting the viral capsid protein, disrupting multiple stages of the viral life cycle including assembly, transport, and replication. This unique mechanism makes it effective against strains resistant to other antiretroviral classes.
Lenacapavir is used in combination with other antiretroviral agents as part of an optimized background regimen. One of its key advantages is its long-acting profile, allowing extended dosing intervals that can improve adherence and treatment continuity. Clinical studies have shown strong antiviral activity, sustained viral load reduction, and a manageable safety profile in patients with limited treatment options. It is marketed under the brand name Sunlenca and developed by Gilead Sciences. Ongoing research is also exploring its role in long-acting preventive strategies and combination regimens for durable HIV management.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing